Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 140

Results For "IMI"

4120 News Found

Suven Pharmaceuticals gets Form 483 from with two observations from USFDA for Casper Pharma
Drug Approval | July 14, 2024

Suven Pharmaceuticals gets Form 483 from with two observations from USFDA for Casper Pharma

The company will address these observations within the stipulated timeline


Alembic announces USFDA tentative approval for Selexipag for Injection, 1,800 mcg/vial
Drug Approval | July 14, 2024

Alembic announces USFDA tentative approval for Selexipag for Injection, 1,800 mcg/vial

Selexipag is a prostacyclin receptor agonist indicated for the treatment of pulmonary arterial hypertension


Veerhealth Care secures export order from US Institutional Supplier
News | July 14, 2024

Veerhealth Care secures export order from US Institutional Supplier

The company is planning to expand its plant capacity in in Vapi


7th India-Japan medical product regulatory symposium held at New Delhi
Policy | July 14, 2024

7th India-Japan medical product regulatory symposium held at New Delhi

Enhanced collaboration under the Memorandum of Cooperation (MoC) between India and Japan in medical product regulations


Lupin receives EIR from USFDA for its Dabhasa  facility
Drug Approval | July 13, 2024

Lupin receives EIR from USFDA for its Dabhasa facility

The facility is a part of Lupin Manufacturing Solutions


KIMS Hospitals acquires 200-bed multi-specialty hospital in Vizag
Healthcare | July 10, 2024

KIMS Hospitals acquires 200-bed multi-specialty hospital in Vizag

KIMS already have a multi-specialty hospital and gastro unit at Vizag


Shilpa Pharma Lifesciences’ Unit 2 Raichur has cleared the ANVISA-Brazil GMP inspection
News | July 10, 2024

Shilpa Pharma Lifesciences’ Unit 2 Raichur has cleared the ANVISA-Brazil GMP inspection

The Unit has been issued GMP Certification from ANVISA-Brazil


Alembic Pharmaceuticals announces USFDA Final Approval for Bromfenac Ophthalmic Solution, 0.07%
Drug Approval | July 10, 2024

Alembic Pharmaceuticals announces USFDA Final Approval for Bromfenac Ophthalmic Solution, 0.07%

The approved ANDA is therapeutically equivalent to the reference listed drug product


Lilly to acquire Morphic to improve outcomes for patients with inflammatory bowel disease
News | July 10, 2024

Lilly to acquire Morphic to improve outcomes for patients with inflammatory bowel disease

Acquisition to expand Lilly's immunology pipeline with oral integrin therapies